Gynecologic Cancer News

Paclitaxel plus carboplatin demonstrated noninferiority to paclitaxel plus ifosfamide and should be a standard treatment for uterine carcinosarcoma, according to results of a phase 3 study published in Journal of Clinical Oncology.

About one-third of women with commercial insurance underwent genetic testing for ovarian cancer between 2008 and 2018 despite unequivocal recommendations for universal testing, according to research in JAMA Network Open.

Among individuals with certain cancers, treatment with radiotherapy was associated with poorer long-term CV-specific survival compared with those who did not undergo radiotherapy, researchers reported.

Daily electronic patient-reported outcome assessments may provide valuable insight into symptom management among patients with cancer undergoing antineoplastic treatment, according to a study published in JAMA Network Open.

B.J. Rimel, MD, has been named medical director of the Cedars-Sinai Cancer Clinical Trials Office.

Critical race theory originated in a legal framework but has implications in the conduct of cancer research, according to Mya L. Roberson, PhD.

Only 7.5% of oncology trials conducted between 2008 and 2020 investigated surgical interventions, according to study results published in JAMA Network Open.

The FDA approved FoundationOne CDx as a companion diagnostic to identify patients with microsatellite instability-high solid tumors who may benefit from pembrolizumab, according to a press release from the test’s manufacturer.

The Fred Hutch/University of Washington Cancer Consortium has announced new leadership.

The FDA cleared investigational new drug applications for three cell therapies in development for oncology indications.